Seres Therapeutics CEO Eric Shaff discusses the patient impact of VOWST, the first ever approved oral microbiome drug for recurrent C.diff, and why this is only the beginning for the microbiome as a new field of medicine. More from Flagship @ JPM2024 here.
Related Companies
- Seres Therapeutics Founded: 2011
